Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.Peer-Reviewed Original ResearchConceptsHuman iNKT cellsINKT cellsCombination therapyAntitumor T-cell immunitySerum soluble IL2 receptorMonocyte-derived dendritic cellsNatural killer T cellsBroad immune activationLow-dose lenalidomideSoluble IL2 receptorCycles of therapyHuman NKT cellsT cell immunityKiller T cellsInnate immune cellsInduction of eosinophiliaActivation of monocytesPrevention of cancerCycles of combinationAsymptomatic myelomaClinical myelomaMeasurable diseaseClinical regressionClinical responseNKT cells